Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Prostate Cancer

Free Subscription Articles published in J Nucl Med Retrieve available abstracts of 108 articles: HTML format

Single Articles

March 2023
1. RAVI P, Whelpley B, Kelly E, Wolanski A, et al
   Clinical Implementation of (177)Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges.
   J Nucl Med. 2023;64:349-350.
   PubMed    
   
   
   February 2023
2. TRAPP C, Oliinyk D, Rogowski P, Von Bestenbostel R, et al
   An analysis of PSMA-PET/CT-positive lymph node distribution and their coverage by different elective nodal radiation volumes in postoperative prostate cancer patients.
   J Nucl Med. 2023 Feb 2:jnumed.122.265159. doi: 10.2967/jnumed.122.265159.
   PubMed     Abstract available
   
   
   January 2023
3. AL JALALI V, Wasinger G, Rasul S, Grubmueller B, et al
   Consecutive PSMA and AR PET imaging shows positive correlation to AR and PSMA protein expression in primary hormone naive prostate cancer.
   J Nucl Med. 2023 Jan 19:jnumed.122.264981. doi: 10.2967/jnumed.122.264981.
   PubMed     Abstract available
   
   
   
4. GUDENKAUF LM, Chavez M, Maconi ML, Geiss C, et al
   Developing a novel patient reported outcomes measure for prostate cancer patients receiving radionuclide therapy.
   J Nucl Med. 2023 Jan 12:jnumed.122.264946. doi: 10.2967/jnumed.122.264946.
   PubMed     Abstract available
   
   
   
5. CALDERONI L, Maietti E, Farolfi A, Mei R, et al
   Prostate-Specific Membrane Antigen Expression on Positron Emission Tomography/Computed Tomography in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study.
   J Nucl Med. 2023 Jan 12:jnumed.122.264964. doi: 10.2967/jnumed.122.264964.
   PubMed     Abstract available
   
   
   December 2022
6. LUNGER L, Chantadisai M, Karimzadeh A, Rauscher I, et al
   The prognostic role of (68)Ga-PSMA11 PET-based response in prostate cancer patients undergoing taxane-based chemotherapy.
   J Nucl Med. 2022 Dec 29:jnumed.122.264962. doi: 10.2967/jnumed.122.264962.
   PubMed     Abstract available
   
   
   
7. SEIFERT R, Telli T, Opitz M, Barbato F, et al
   Non-specific PSMA-1007 bone uptake evaluated through PSMA-11 PET, bone scan and MRI triple validation in patients with biochemical recurrence of prostate cancer.
   J Nucl Med. 2022 Dec 2:jnumed.118.215434. doi: 10.2967/jnumed.118.215434.
   PubMed     Abstract available
   
   
   
8. PERERA M, Morris MJ
   From Concept to Regulatory Drug Approval: Lessons for Theranostics.
   J Nucl Med. 2022;63:1793-1801.
   PubMed     Abstract available
   
   
   
9. HERRMANN K, Giovanella L, Santos A, Gear J, et al
   Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center.
   J Nucl Med. 2022;63:1836-1843.
   PubMed     Abstract available
   
   
   November 2022
10. OLIVIER P, Giraudet AL, Skanjeti A, Merlin C, et al
    Phase III study of (18)F-PSMA-1007 versus (18)F-fluorocholine PET/CT for localization of prostate cancer biochemical recurrence: a prospective, randomized, cross-over, multicenter study.
    J Nucl Med. 2022 Nov 23:jnumed.122.264743. doi: 10.2967/jnumed.122.264743.
    PubMed     Abstract available
    
    
    
11. DUAN H, Ghanouni P, Daniel B, Rosenberg J, et al
    A Pilot Study of (68)Ga-PSMA11 and (68)Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer.
    J Nucl Med. 2022 Nov 17. pii: jnumed.122.264448. doi: 10.2967/jnumed.122.264448.
    PubMed     Abstract available
    
    
    
12. FRAGOSO COSTA P, Pullen L, Kesch C, Krafft U, et al
    F18-PSMA Cerenkov luminescence and flexible autoradiography Imaging in a prostate cancer mouse model and first results of a radical prostatectomy feasibility study in men.
    J Nucl Med. 2022 Nov 10. pii: jnumed.122.264670. doi: 10.2967/jnumed.122.264670.
    PubMed     Abstract available
    
    
    
13. DUAN H, Ghanouni P, Daniel B, Rosenberg J, et al
    A Pilot Study of (68)Ga-PSMA11 and (68)Ga-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High Intensity Focused Ultrasound (HIFU) Therapy.
    J Nucl Med. 2022 Nov 3. pii: jnumed.122.264783. doi: 10.2967/jnumed.122.264783.
    PubMed     Abstract available
    
    
    
14. WANG G, Zang J, Jiang Y, Liu Q, et al
    A single-arm, low-dose, prospective study of (177)Lu-EB-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer.
    J Nucl Med. 2022 Nov 3. pii: jnumed.122.264857. doi: 10.2967/jnumed.122.264857.
    PubMed     Abstract available
    
    
    
15. JADVAR H, Abreu AL, Ballas LK, Quinn DI, et al
    Oligometastatic Prostate Cancer: Current Status and Future Challenges.
    J Nucl Med. 2022;63:1628-1635.
    PubMed     Abstract available
    
    
    October 2022
16. COOK GJR, Wong WL, Sanghera B, Mangar S, et al
    Eligibility for (177)Lu-PSMA therapy depends on the choice of companion diagnostic tracer: a comparison of (68)Ga-PSMA-11 and (99m)Tc-MIP-1404 in metastatic castrate resistant prostate cancer.
    J Nucl Med. 2022 Oct 27. pii: jnumed.122.264296. doi: 10.2967/jnumed.122.264296.
    PubMed     Abstract available
    
    
    
17. RAHBAR K, Essler M, Pabst KM, Eiber M, et al
    Safety and Survival Outcomes of Lutetium-177-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with prior Radium-223 treatment: The RALU Study.
    J Nucl Med. 2022 Oct 27. pii: jnumed.122.264456. doi: 10.2967/jnumed.122.264456.
    PubMed     Abstract available
    
    
    
18. PHELPS TE, Harmon SA, Mena E, Lindenberg L, et al
    Predicting Outcomes of Indeterminate Bone Lesions on (18)F-DCFPyL PSMA PET/CT Scans in the Setting of High-Risk Primary or Recurrent Prostate Cancer.
    J Nucl Med. 2022 Oct 20. pii: jnumed.122.264334. doi: 10.2967/jnumed.122.264334.
    PubMed     Abstract available
    
    
    
19. SATHEKGE M, Bruchertseifer F, Vorster M, Lawal IO, et al
    mCRPC Patients Receiving (225)Ac-PSMA-617 Therapy in the Post-Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis.
    J Nucl Med. 2022;63:1496-1502.
    PubMed     Abstract available
    
    
    September 2022
20. KARIMZADEH A, Heck M, Tauber R, Knorr K, et al
    (177)Lu-PSMA-I&T for treatment of metastatic castration resistant prostate cancer: prognostic value of scintigraphic and clinical biomarkers.
    J Nucl Med. 2022 Sep 22. pii: jnumed.122.264402. doi: 10.2967/jnumed.122.264402.
    PubMed     Abstract available
    
    
    
21. JOHN N, Pathmanandavel S, Crumbaker M, Counter W, et al
    (177)Lu-PSMA SPECT Quantitation at 6 Weeks (dose 2) Predicts Short Progression Free Survival for Patients Undergoing Lu PSMA I&T Therapy.
    J Nucl Med. 2022 Sep 8. pii: jnumed.122.264677. doi: 10.2967/jnumed.122.264677.
    PubMed     Abstract available
    
    
    
22. SCHOLLHAMMER R, Robert G, Asselineau J, Yacoub M, et al
    Comparison of (68)Ga-PSMA-617 PET/CT and (68)Ga-RM2 PET/CT in patients with localized prostate cancer candidate for radical prostatectomy: a prospective, single arm, single center, phase II study.
    J Nucl Med. 2022 Sep 2. pii: jnumed.122.263889. doi: 10.2967/jnumed.122.263889.
    PubMed     Abstract available
    
    
    
23. BELLAVIA MC, Patel RB, Anderson CJ
    Combined Targeted Radiopharmaceutical Therapy and Immune Checkpoint Blockade: From Preclinical Advances to the Clinic.
    J Nucl Med. 2022 Sep 2. pii: jnumed.122.264373. doi: 10.2967/jnumed.122.264373.
    PubMed     Abstract available
    
    
    
24. KLOSE JM, Wosniack J, Iking J, Staniszewska M, et al
    Administration Routes for SSTR-/PSMA- and FAP-Directed Theranostic Radioligands in Mice.
    J Nucl Med. 2022;63:1357-1363.
    PubMed     Abstract available
    
    
    
25. COSTA PF, Fendler WP, Herrmann K, Sandach P, et al
    Radiation Protection and Occupational Exposure on (68)Ga-PSMA-11-Based Cerenkov Luminescence Imaging Procedures in Robot-Assisted Prostatectomy.
    J Nucl Med. 2022;63:1349-1356.
    PubMed     Abstract available
    
    
    August 2022
26. HAGENS MJ, Oprea-Lager DE, Vis AN, Wondergem M, et al
    Reproducibility of PSMA PET/CT Imaging for primary staging of treatment-naive prostate cancer patients depends on the applied radiotracer: a retrospective study.
    J Nucl Med. 2022 Aug 25. pii: jnumed.121.263139. doi: 10.2967/jnumed.121.263139.
    PubMed     Abstract available
    
    
    
27. PATHMANANDAVEL S, Crumbaker M, Ho B, Yam AO, et al
    Evaluation of (177)Lu-PSMA SPECT Quantitation as a Response Biomarker within a Prospective (177)Lu-PSMA-617 and NOX66 Combination Trial (LuPIN).
    J Nucl Med. 2022 Aug 25. pii: jnumed.122.264398. doi: 10.2967/jnumed.122.264398.
    PubMed     Abstract available
    
    
    
28. BEYER T, Czernin J, Freudenberg LS, Giesel F, et al
    A 2022 INTERNATIONAL SURVEY ON THE STATUS OF PROSTATE CANCER THERANOSTICS.
    J Nucl Med. 2022 Aug 11. pii: jnumed.122.264298. doi: 10.2967/jnumed.122.264298.
    PubMed     Abstract available
    
    
    July 2022
29. DERLIN T, Widjaja L, Werner RA, Bengel FM, et al
    (177)Lu-PSMA for Extended Treatment of Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2022 Jul 19. pii: jnumed.122.264293. doi: 10.2967/jnumed.122.264293.
    PubMed     Abstract available
    
    
    
30. KOEHLER D, Sauer M, Klutmann S, Apostolova I, et al
    Feasibility of (99m)Tc-MIP-1404 for SPECT/CT imaging and subsequent PSMA-radioguided surgery in early biochemical recurrent prostate cancer: a case series of 9 patients.
    J Nucl Med. 2022 Jul 14. pii: jnumed.122.263892. doi: 10.2967/jnumed.122.263892.
    PubMed     Abstract available
    
    
    
31. HOFLING AA, Fotenos AF, Niu G, Fallah J, et al
    Prostate Cancer Theranostics: Concurrent Approvals by the Food and Drug Administration of the First Diagnostic Imaging Drug Indicated to Select Patients for a Paired Radioligand Therapeutic Drug.
    J Nucl Med. 2022 Jul 7. pii: jnumed.122.264299. doi: 10.2967/jnumed.122.264299.
    PubMed    
    
    
    
32. PAINDELLI C, Casarin S, Wang F, Diaz-Gomez L, et al
    Enhancing (223)Ra Treatment Efficacy by Anti-beta1 Integrin Targeting.
    J Nucl Med. 2022;63:1039-1045.
    PubMed     Abstract available
    
    
    June 2022
33. PATHMANANDAVEL S, Crumbaker M, Nguyen A, Yam AOW, et al
    The prognostic value of post-treatment PSMA and FDG PET/CT in metastatic, castration-resistant prostate cancer treated with (177)LuPSMA-617 and NOX66 in a phase I/II trial (LuPIN).
    J Nucl Med. 2022 Jun 23. pii: jnumed.122.264104. doi: 10.2967/jnumed.122.264104.
    PubMed     Abstract available
    
    
    
34. SIEBINGA H, Olde Heuvel J, Rijkhorst EJ, Hendrikx JJMA, et al
    The Impact of Peptide Amount on Tumor Uptake to Assess PSMA Receptor Saturation on (68)Ga-PSMA-11 PET/CT in Primary Prostate Cancer Patients.
    J Nucl Med. 2022 Jun 9. pii: jnumed.122.264101. doi: 10.2967/jnumed.122.264101.
    PubMed     Abstract available
    
    
    
35. POMYKALA KL, Herrmann K, Padhani AR, Hofman MS, et al
    Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Prostate Cancer: We have the answers.
    J Nucl Med. 2022 Jun 9. pii: jnumed.122.264394. doi: 10.2967/jnumed.122.264394.
    PubMed    
    
    
    
36. SARTOR O, Herrmann K
    Prostate Cancer Treatment: (177)Lu-PSMA-617 Considerations, Concepts, and Limitations.
    J Nucl Med. 2022;63:823-829.
    PubMed     Abstract available
    
    
    
37. JADVAR H
    The VISION Forward: Recognition and Implication of PSMA-/(18)F-FDG+ mCRPC.
    J Nucl Med. 2022;63:812-815.
    PubMed     Abstract available
    
    
    May 2022
38. SARTOR O
    Invited Perspective, Outcome of patients with PSMA-PET/CT screen failure by VISION criteria and treated with 177Lu-PSMA therapy: a multicenter retrospective analysis.
    J Nucl Med. 2022 May 26. pii: jnumed.122.264128. doi: 10.2967/jnumed.122.264128.
    PubMed    
    
    
    
39. DUAN H, Baratto L, Fan RE, Soerensen SJC, et al
    Correlation of (68)Ga-RM2 PET with Post-Surgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer.
    J Nucl Med. 2022 May 12. pii: jnumed.122.263971. doi: 10.2967/jnumed.122.263971.
    PubMed     Abstract available
    
    
    
40. MORADI F, Duan H, Song H, Davidzon GA, et al
    (68)Ga-PSMA-11 PET/MRI in patients with newly diagnosed intermediate or high-risk prostate adenocarcinoma: PET findings correlate with outcomes after definitive treatment.
    J Nucl Med. 2022 May 5. pii: jnumed.122.263897. doi: 10.2967/jnumed.122.263897.
    PubMed     Abstract available
    
    
    
41. 
    FDA Approves Pluvicto/Locametz for Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2022;63:13N.
    PubMed    
    
    
    April 2022
42. DENIS CES, Cousin FC, De Laere B, Hustinx R, et al
    Using, (68)Ga-PSMA-11 PET/CT for therapy response assessment in patients with metastatic castration-resistant prostate cancer: an application of EAU/EANM recommendations in clinical practice.
    J Nucl Med. 2022 Apr 21. pii: jnumed.121.263611. doi: 10.2967/jnumed.121.263611.
    PubMed     Abstract available
    
    
    
43. GAFITA A, Rauscher I, Weber M, Hadaschik B, et al
    Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study.
    J Nucl Med. 2022 Apr 14. pii: jnumed.121.263072. doi: 10.2967/jnumed.121.263072.
    PubMed     Abstract available
    
    
    
44. KROENKE M, Schweiger L, Horn T, Haller B, et al
    Validation of (18)F-rhPSMA-7 and (18)F-rhPSMA-7.3 PET imaging results with histopathology from salvage surgery in patients with biochemical recurrence of prostate cancer.
    J Nucl Med. 2022 Apr 7. pii: jnumed.121.263707. doi: 10.2967/jnumed.121.263707.
    PubMed     Abstract available
    
    
    March 2022
45. EMMETT LM, Papa N, Buteau J, Ho B, et al
    The PRIMARY Score: Using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer diagnosis.
    J Nucl Med. 2022 Mar 17. pii: jnumed.121.263448. doi: 10.2967/jnumed.121.263448.
    PubMed     Abstract available
    
    
    
46. ILHAN H, Kroenke M, Wurzer A, Unterrainer M, et al
    (18)F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer after Curative-intent Radiation Therapy: A Bicentric Retrospective Study.
    J Nucl Med. 2022 Mar 10. pii: jnumed.121.262861. doi: 10.2967/jnumed.121.262861.
    PubMed     Abstract available
    
    
    
47. HOTTA M, Gafita A, Czernin J, Calais J, et al
    Outcome of patients with PSMA-PET/CT screen failure by VISION criteria and treated with (177)Lu-PSMA therapy: a multicenter retrospective analysis.
    J Nucl Med. 2022 Mar 10. pii: jnumed.121.263441. doi: 10.2967/jnumed.121.263441.
    PubMed     Abstract available
    
    
    
48. NOTOHAMIPRODJO S, Eiber M, Lohrmann C, Weber WA, et al
    Temporary reactive response of axillary lymph nodes to COVID-19 vaccination on (18)F-rhPSMA-7.3 PET/CT in patients with prostate cancer.
    J Nucl Med. 2022 Mar 3. pii: jnumed.121.263758. doi: 10.2967/jnumed.121.263758.
    PubMed     Abstract available
    
    
    
49. GONDOPUTRO W, Scheltema MJ, Blazevski A, Doan P, et al
    Robot-assisted prostate-specific membrane antigen-radioguided surgery in primary diagnosed prostate cancer.
    J Nucl Med. 2022 Mar 3. pii: jnumed.121.263743. doi: 10.2967/jnumed.121.263743.
    PubMed     Abstract available
    
    
    February 2022
50. WU WY, Yu F, Zhang PJ, Bu T, et al
    (68)Ga-DOTA-NT-20.3 Neurotensin receptor 1 positron emission tomography imaging as a surrogate for neuroendocrine differentiation of prostate cancer.
    J Nucl Med. 2022 Feb 17. pii: jnumed.121.263132. doi: 10.2967/jnumed.121.263132.
    PubMed     Abstract available
    
    
    
51. 
    FDA Approves New (68)Ga Kit for Prostate Cancer PET.
    J Nucl Med. 2022;63:26N.
    PubMed    
    
    
    
52. SARTOR O
    Reply: A VISION of ALSYMPCA.
    J Nucl Med. 2022;63:324-325.
    PubMed    
    
    
    
53. SCHIAVOM DUARTE P
    A VISION of ALSYMPCA.
    J Nucl Med. 2022;63:324.
    PubMed    
    
    
    
54. MEASE RC, Kang CM, Kumar V, Banerjee SR, et al
    An Improved (211)At-Labeled Agent for PSMA-Targeted alpha-Therapy.
    J Nucl Med. 2022;63:259-267.
    PubMed     Abstract available
    
    
    January 2022
55. WURZER A, Kunert JP, Fischer S, Felber V, et al
    Synthesis and Preclinical Evaluation of (177)Lu-labeled Radiohybrid PSMA Ligands (rhPSMAs) for Endoradiotherapy of Prostate Cancer.
    J Nucl Med. 2022 Jan 27. pii: jnumed.121.263371. doi: 10.2967/jnumed.121.263371.
    PubMed     Abstract available
    
    
    
56. KORSEN JA, Kalidindi TM, Khitrov S, Samuels ZV, et al
    Molecular imaging of Neuroendocrine Prostate Cancer by targeting Delta-like Ligand 3.
    J Nucl Med. 2022 Jan 20. pii: jnumed.121.263221. doi: 10.2967/jnumed.121.263221.
    PubMed     Abstract available
    
    
    
57. SUTERA P, Phillips RM, Deek M, Ozyigit G, et al
    The Promise of Metastasis-Directed Therapy for Oligometastatic Prostate Cancer - Going Beneath the Surface with Molecular Imaging.
    J Nucl Med. 2022 Jan 20. pii: jnumed.121.263684. doi: 10.2967/jnumed.121.263684.
    PubMed    
    
    
    
58. NG M, Guerrieri M, Wong LM, Taubman K, et al
    The change in management by (18)F-DCFPyL PSMA PET scanning in patients undergoing post-prostatectomy radiotherapy, with early biochemical response outcomes.
    J Nucl Med. 2022 Jan 20. pii: jnumed.121.263521. doi: 10.2967/jnumed.121.263521.
    PubMed     Abstract available
    
    
    
59. LANGBEIN T, Wang H, Rauscher I, Kronke M, et al
    Utility of (18)F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.
    J Nucl Med. 2022 Jan 6. pii: jnumed.121.263440. doi: 10.2967/jnumed.121.263440.
    PubMed     Abstract available
    
    
    
60. CHEN R, Wang Y, Zhu Y, Shi Y, et al
    The Added Value of (18)F-FDG PET/CT Compared with (68)Ga-PSMA PET/CT in Patients with Castration-Resistant Prostate Cancer.
    J Nucl Med. 2022;63:69-75.
    PubMed     Abstract available
    
    
    December 2021
61. MENA E, Rowe SP, Shih JH, Lindenberg L, et al
    Predictors of (18)F-DCFPyL-PET/CT Positivity in Patients with Biochemical Recurrence of Prostate Cancer After Local Therapy.
    J Nucl Med. 2021 Dec 16. pii: jnumed.121.262347. doi: 10.2967/jnumed.121.262347.
    PubMed     Abstract available
    
    
    
62. SCHUCHARDT C, Zhang J, Kulkarni HR, Chen X, et al
    Prostate-specific membrane antigen radioligand therapy using (177)Lu-PSMA I&T and (177)Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution and dosimetry.
    J Nucl Med. 2021 Dec 9. pii: jnumed.121.262713. doi: 10.2967/jnumed.121.262713.
    PubMed     Abstract available
    
    
    November 2021
63. SHAGERA QA, Artigas C, Karfis I, Critchi G, et al
    (68)Ga-PSMA PET/CT for response assessment and outcome prediction in metastatic prostate cancer patients treated with taxane-based chemotherapy.
    J Nucl Med. 2021 Nov 12. pii: jnumed.121.263006. doi: 10.2967/jnumed.121.263006.
    PubMed     Abstract available
    
    
    
64. CALAIS J, Czernin J
    PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy.
    J Nucl Med. 2021;62:1489-1491.
    PubMed    
    
    
    
65. SRINIVAS S, Iagaru A
    To Scan or Not to Scan: An Unnecessary Dilemma for PSMA Radioligand Therapy.
    J Nucl Med. 2021;62:1487-1488.
    PubMed    
    
    
    October 2021
66. MIYAHIRA AK, Soule HR
    The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Foundational Role of the Prostate Cancer Foundation.
    J Nucl Med. 2021 Oct 21. pii: jnumed.121.262997. doi: 10.2967/jnumed.121.262997.
    PubMed     Abstract available
    
    
    
67. SONNI I, Felker ER, Lenis AT, Sisk AE, et al
    Head-to-head comparison of (68)Ga-PSMA-11 PET/CT and mpMRI with histopathology gold-standard in the detection, intra-prostatic localization and local extension of primary prostate cancer: results from a prospective single-center imaging trial.
    J Nucl Med. 2021 Oct 14. pii: jnumed.121.262398. doi: 10.2967/jnumed.121.262398.
    PubMed     Abstract available
    
    
    
68. CALAIS J, Czernin J, Thin P, Gartmann J, et al
    Safety of PSMA-Targeted Molecular Radioligand Therapy with (177)Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312).
    J Nucl Med. 2021;62:1447-1456.
    PubMed     Abstract available
    
    
    
69. NOTNI J
    PSMA-Targeted Therapeutics: A Tale About Law and Economics.
    J Nucl Med. 2021;62:1482.
    PubMed    
    
    
    
70. EDER AC, Schafer M, Schmidt J, Bauder-Wust U, et al
    Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules.
    J Nucl Med. 2021;62:1461-1467.
    PubMed     Abstract available
    
    
    September 2021
71. FEUERECKER B, Chantadisai M, Allmann A, Tauber R, et al
    Pre-therapeutic comparative dosimetry of (177)Lu-rhPSMA-7.3 and (177)Lu-PSMAI&T in patients with metastatic castration resistant prostate cancer (mCRPC).
    J Nucl Med. 2021 Sep 16. pii: jnumed.121.262671. doi: 10.2967/jnumed.121.262671.
    PubMed     Abstract available
    
    
    
72. LEE DY, Kim YI
    Effects of (225)Ac-labeled prostate-specific membrane antigen radioligand therapy in metastatic castration-resistant prostate cancer: A meta-analysis.
    J Nucl Med. 2021 Sep 9. pii: jnumed.121.262017. doi: 10.2967/jnumed.121.262017.
    PubMed     Abstract available
    
    
    
73. FOURQUET A, Rosenberg A, Mena E, Shih JJ, et al
    A comparison of (18)F-DCFPyL, (18)F-NaF and (18)F-FDG PET/CT in a prospective cohort of men with metastatic prostate cancer.
    J Nucl Med. 2021 Sep 2. pii: jnumed.121.262371. doi: 10.2967/jnumed.121.262371.
    PubMed     Abstract available
    
    
    
74. WAHL RL
    Progress in Prostate Cancer Theranostics.
    J Nucl Med. 2021;62:11N.
    PubMed    
    
    
    
75. BRENNER W, Strobel J, Prasad V
    PSMA Theranostics: Is the Time Ripe to Pave the Way to Further Tumor Entities?
    J Nucl Med. 2021;62:1242-1243.
    PubMed    
    
    
    August 2021
76. SEIFERT R, Sandach P, Kersting D, Fendler WP, et al
    Repeatability of (68)Ga-PSMA-HBED-CC PET/CT-derived total molecular tumor volume.
    J Nucl Med. 2021 Aug 26. pii: jnumed.121.262528. doi: 10.2967/jnumed.121.262528.
    PubMed     Abstract available
    
    
    
77. PARIHAR AS, Schmidt LR, Dehdashti F, Wahl RL, et al
    Detection of additional primary neoplasms on (18)F-Fluciclovine PET/CT in patients with primary prostate cancer.
    J Nucl Med. 2021 Aug 19. pii: jnumed.121.262647. doi: 10.2967/jnumed.121.262647.
    PubMed     Abstract available
    
    
    
78. SANDHU S, Guo C, Hofman MS
    Radionuclide Therapy in Prostate Cancer: from standalone to combination PSMA theranostics.
    J Nucl Med. 2021 Aug 12. pii: jnumed.120.243295. doi: 10.2967/jnumed.120.243295.
    PubMed     Abstract available
    
    
    
79. LANGBEIN T, Wurzer A, Gafita A, Robertson A, et al
    The Influence of Specific Activity on the Biodistribution of (18)F-rhPSMA-7.3: A Retrospective Analysis of Clinical Positron Emission Tomography Data.
    J Nucl Med. 2021 Aug 12. pii: jnumed.121.262471. doi: 10.2967/jnumed.121.262471.
    PubMed     Abstract available
    
    
    
80. 
    FDA Approves (18)F-DCFPyL PET Agent in Prostate Cancer.
    J Nucl Med. 2021;62:11N.
    PubMed    
    
    
    
81. 
    FDA Approves (18)F-DCFPyL PET Agent in Prostate Cancer.
    J Nucl Med. 2021;62:11N.
    PubMed    
    
    
    
82. CZERNIN J, Calais J
    (177)Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine.
    J Nucl Med. 2021;62:1025-1026.
    PubMed    
    
    
    
83. YUSUFI N, Wurzer A, Herz M, D'Alessandria C, et al
    Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using (19)F/(177)Lu-rhPSMA-7.3 and (177)Lu-PSMA I&T.
    J Nucl Med. 2021;62:1106-1111.
    PubMed     Abstract available
    
    
    
84. FERNANDEZ R, Eppard E, Lehnert W, Jimenez-Franco LD, et al
    Evaluation of Safety and Dosimetry of (177)Lu-DOTA-ZOL for Therapy of Bone Metastases.
    J Nucl Med. 2021;62:1126-1132.
    PubMed     Abstract available
    
    
    
85. URBAN S, Meyer C, Dahlbom M, Farkas I, et al
    Radiation Dosimetry of (99m)Tc-PSMA I&S: A Single-Center Prospective Study.
    J Nucl Med. 2021;62:1075-1081.
    PubMed     Abstract available
    
    
    July 2021
86. DIETLEIN F, Kobe C, Munoz Vazquez S, Fischer T, et al
    An (89)Zr-labeled PSMA tracer for PET/CT imaging of prostate cancer patients.
    J Nucl Med. 2021 Jul 29. pii: jnumed.121.262290. doi: 10.2967/jnumed.121.262290.
    PubMed     Abstract available
    
    
    
87. DONG L, Su Y, Zhu Y, Markowski MC, et al
    The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer after Radical Prostatectomy.
    J Nucl Med. 2021 Jul 29. pii: jnumed.121.262411. doi: 10.2967/jnumed.121.262411.
    PubMed     Abstract available
    
    
    
88. PATHMANANDAVEL S, Crumbaker M, Yam AO, Nguyen A, et al
    (177)Lutetium PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castrate-resistant prostate cancer (LuPIN): Patient outcomes and predictors of treatment response of a Phase I/II trial.
    J Nucl Med. 2021 Jul 29. pii: jnumed.121.262552. doi: 10.2967/jnumed.121.262552.
    PubMed     Abstract available
    
    
    
89. ABGHARI-GERST M, Armstrong WR, Nguyen K, Calais J, et al
    A comprehensive assessment of (68)Ga-PSMA-11 PET in biochemically recurrent prostate cancer: Results from a prospective multi-center study in 2005 patients.
    J Nucl Med. 2021 Jul 29. pii: jnumed.121.262412. doi: 10.2967/jnumed.121.262412.
    PubMed     Abstract available
    
    
    
90. BENARD F, Bratanovic IJ
    A Novel Radiotracer for Molecular Imaging and Therapy of Gastrin-Releasing Peptide Receptor Positive Prostate Cancer.
    J Nucl Med. 2021 Jul 22. pii: jnumed.120.257758. doi: 10.2967/jnumed.120.257758.
    PubMed     Abstract available
    
    
    
91. CERCI JJ, Fanti S, Lobato EE, Kunikowska J, et al
    Diagnostic performance and clinical impact of (68)Ga-PSMA-11 imaging in early relapsed prostate cancer after radical therapy: a prospective multicenter study (IAEA-PSMA study).
    J Nucl Med. 2021 Jul 2. pii: jnumed.120.261886. doi: 10.2967/jnumed.120.261886.
    PubMed     Abstract available
    
    
    June 2021
92. SARTOR AO, la Fougere C, Essler M, Ezziddin S, et al
    Lutetium-177-prostate-specific membrane antigen ligand following radium-223 treatment in men with bone-metastatic castration-resistant prostate cancer: real-world clinical experience.
    J Nucl Med. 2021 Jun 24. pii: jnumed.121.262240. doi: 10.2967/jnumed.121.262240.
    PubMed     Abstract available
    
    
    
93. MIX M, Renaud T, Kind F, Nemer U, et al
    Kidney doses in (177)Lu-based radioligand therapy in prostate cancer: Is dose estimation based on reduced dosimetry measurements feasible?
    J Nucl Med. 2021 Jun 4. pii: jnumed.121.262245. doi: 10.2967/jnumed.121.262245.
    PubMed     Abstract available
    
    
    
94. MCINNES LE, Cullinane C, Roselt PD, Jackson S, et al
    Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with (67)Cu.
    J Nucl Med. 2021;62:829-832.
    PubMed     Abstract available
    
    
    May 2021
95. NICKOLS N, Anand A, Johnsson K, Brynolfsson J, et al
    aPROMISE: A Novel Automated-PROMISE platform to Standardize Evaluation of Tumor Burden in (18)F-DCFPyL (PSMA) images of Veterans with Prostate Cancer.
    J Nucl Med. 2021 May 28. pii: jnumed.120.261863. doi: 10.2967/jnumed.120.261863.
    PubMed     Abstract available
    
    
    
96. GAFITA A, Wang H, Robertson A, Armstrong WR, et al
    Tumor sink effect in (68)Ga-PSMA-11 PET: Myth or Reality?
    J Nucl Med. 2021 May 28. pii: jnumed.121.261906. doi: 10.2967/jnumed.121.261906.
    PubMed     Abstract available
    
    
    
97. CALAIS J, Gafita A, Eiber MR, Armstrong WR, et al
    Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with (177)Lu-PSMA-617 for metastatic Castration-reSISTant Prostate Cancer (RESIST-PC): Efficacy results of the UCLA cohort.
    J Nucl Med. 2021 May 20. pii: jnumed.121.261982. doi: 10.2967/jnumed.121.261982.
    PubMed     Abstract available
    
    
    
98. BARBATO F, Fendler WP, Rauscher I, Herrmann K, et al
    PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of disease.
    J Nucl Med. 2021 May 14. pii: jnumed.121.262120. doi: 10.2967/jnumed.121.262120.
    PubMed     Abstract available
    
    
    
99. TREIBER H, Koenig A, Neesse A, Richter A, et al
    Liver enzyme elevation after (177)Lu-PSMA radioligand therapy for metastasized castration-resistant prostate cancer.
    J Nucl Med. 2021 May 14. pii: jnumed.120.258533. doi: 10.2967/jnumed.120.258533.
    PubMed     Abstract available
    
    
    
100. ZACHERL MJ, Gildehaus FJ, Mittlmeier L, Boning G, et al
     First Clinical Results for PSMA-Targeted alpha-Therapy Using (225)Ac-PSMA-I&T in Advanced-mCRPC Patients.
     J Nucl Med. 2021;62:669-674.
     PubMed     Abstract available
     
     
     April 2021
101. FENDLER WP, Farolfi A
     REPLY: The importance of an adequate surgical template during salvage lymph node dissection for node-recurrent prostate cancer.
     J Nucl Med. 2021 Apr 30. pii: jnumed.121.262271. doi: 10.2967/jnumed.121.262271.
     PubMed    
     
     
     
102. OLDE HEUVEL J, de Wit-van der Veen BJ, van der Poel HG, van Leeuwen PJ, et al
     Cerenkov Luminescence Imaging in prostate cancer: not the only light that shines.
     J Nucl Med. 2021 Apr 30. pii: jnumed.120.260034. doi: 10.2967/jnumed.120.260034.
     PubMed     Abstract available
     
     
     
103. CHEN R, Wang Y, Zhu Y, Shi Y, et al
     The added value of (18)F-FDG PET/CT compared to (68)Ga-PSMA PET/CT in patients with castration-resistant prostate cancer.
     J Nucl Med. 2021 Apr 23. pii: jnumed.121.262250. doi: 10.2967/jnumed.121.262250.
     PubMed     Abstract available
     
     
     
104. BRAVI CA, Fossati N, Gandaglia G, Suardi N, et al
     The importance of an adequate surgical template during salvage lymph node dissection for node-recurrent prostate cancer.
     J Nucl Med. 2021 Apr 16. pii: jnumed.121.262104. doi: 10.2967/jnumed.121.262104.
     PubMed    
     
     
     March 2021
105. RITT P, Jobic C, Beck M, Schmidkonz C, et al
     Dissimilar DNA Damage to Blood Lymphocytes After (177)Lu-Labeled DOTATOC or Prostate-Specific Membrane Antigen Therapy.
     J Nucl Med. 2021;62:379-385.
     PubMed     Abstract available
     
     
     November 2020
106. MEIJER D, Donswijk ML, Bodar YJL, van Leeuwen PJ, et al
     Biochemical Persistence of Prostate-specific Antigen after Robot-assisted Laparoscopic Radical Prostatectomy: Tumor localizations using PSMA PET/CT imaging.
     J Nucl Med. 2020 Nov 6. pii: jnumed.120.252528. doi: 10.2967/jnumed.120.252528.
     PubMed     Abstract available
     
     
     October 2020
107. LODGE MA, Lesniak W, Gorin MA, Pienta KJ, et al
     Measurement of PET Quantitative Bias In Vivo.
     J Nucl Med. 2020 Oct 9. pii: jnumed.120.251397. doi: 10.2967/jnumed.120.251397.
     PubMed     Abstract available
     
     
     September 2020
108. FAROLFI A, Hirmas N, Gafita A, Weber M, et al
     PSMA-PET identifies PCWG3 target populations with superior accuracy and reproducibility when compared to conventional imaging: a multicenter retrospective study.
     J Nucl Med. 2020 Sep 11. pii: jnumed.120.246603. doi: 10.2967/jnumed.120.246603.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: